Literature DB >> 22773125

The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT.

S Giebel1, M Labopin, M Mohty, G J Mufti, D Niederwieser, J J Cornelissen, J J W M Janssen, N Milpied, L Vindelov, E Petersen, R Arnold, A Bacigalupo, D Blaise, C Craddock, A Nagler, F Frassoni, M Sadus-Wojciechowska, V Rocha.   

Abstract

Allogeneic hematopoietic SCT with reduced-intensity conditioning (RIC-HSCT) is increasingly adopted for the treatment of older adults with AML. Our goal was to verify for the first time, if center experience influences outcome of RIC-HSCT. Results of 1413 transplantations from HLA-matched related or unrelated donors for adult patients with AML in first CR were analyzed according to the level of center activity. Transplants were performed in 203 European centers between 2001 and 2007. The 2-year probability of leukemia-free survival (LFS) after RIC-HSCT performed in centers with the lowest activity (< or =15 procedures/7 years) was 43±3% compared with 55±2% in the remainder (P<0.001). The incidence of non-relapse mortality (NRM) was 24±3% and 15±1% (P=0.004), whilst relapse rate was 33±3% and 31±1% (P=0.33), respectively. In a multivariate model, adjusted for other prognostic factors, low RIC-HSCT activity was associated with decreased chance of LFS (hazard ratio (HR)=0.64; P<0.001) and increased risk of NRM (HR=1.47, P=0.04) and relapse (HR=1.41, P=0.01). Center experience is a very important predictor of outcome and should be considered in future analyses evaluating the results of RIC-HSCT. The reasons why centers with low RIC-HSCT activity have worse outcomes should be further investigated.

Entities:  

Mesh:

Year:  2012        PMID: 22773125     DOI: 10.1038/bmt.2012.131

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

1.  Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.

Authors:  Sebastian Giebel; Myriam Labopin; Adalberto Ibatici; Paul Browne; Tomasz Czerw; Gerard Socie; Ali Unal; Slawomira Kyrcz-Krzemien; Andrea Bacigalupo; Hakan Goker; Mike Potter; Caroline L Furness; Grant McQuaker; Dietrich Beelen; Noel Milpied; Antonio Campos; Charles Craddock; Arnon Nagler; Mohamad Mohty
Journal:  Oncologist       Date:  2016-02-11

2.  T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis.

Authors:  Norbert-Claude Gorin; Myriam Labopin; Simona Piemontese; William Arcese; Stella Santarone; He Huang; Giovanna Meloni; Felicetto Ferrara; Dietrich Beelen; Miguel Sanz; Andrea Bacigalupo; Fabio Ciceri; Audrey Mailhol; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

3.  Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Sebastian Giebel; Myriam Labopin; Gerard Socié; Dietrich Beelen; Paul Browne; Liisa Volin; Slawomira Kyrcz-Krzemien; Ibrahim Yakoub-Agha; Mahmoud Aljurf; Depei Wu; Mauricette Michallet; Renate Arnold; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2016-09-29       Impact factor: 9.941

4.  Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  F Baron; M Labopin; D Blaise; L Lopez-Corral; S Vigouroux; C Craddock; M Attal; P Jindra; H Goker; G Socié; P Chevallier; P Browne; A Sandstedt; R F Duarte; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

5.  Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience.

Authors:  Igne Kairiene; Ramune Pasauliene; Nadezda Lipunova; Goda Vaitkeviciene; Lina Rageliene; Jelena Rascon
Journal:  Eur J Pediatr       Date:  2017-08-15       Impact factor: 3.183

Review 6.  Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.

Authors:  Salyka Sengsayadeth; Bipin N Savani; Didier Blaise; Florent Malard; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2015-07       Impact factor: 9.941

Review 7.  Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Authors:  Peter Dreger; Johannes Schetelig; Niels Andersen; Paolo Corradini; Michel van Gelder; John Gribben; Eva Kimby; Mauricette Michallet; Carol Moreno; Stephan Stilgenbauer; Emili Montserrat
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

8.  Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.

Authors:  F Khanim; N Davies; P Veliça; R Hayden; J Ride; C Pararasa; M G Chong; U Gunther; N Veerapen; P Winn; R Farmer; E Trivier; L Rigoreau; M Drayson; C Bunce
Journal:  Br J Cancer       Date:  2014-02-25       Impact factor: 7.640

9.  Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.

Authors:  Alois Gratwohl; Anna Sureda; Helen Baldomero; Michael Gratwohl; Peter Dreger; Nicolaus Kröger; Per Ljungman; Eoin McGrath; Mohamad Mohty; Arnon Nagler; Alessandro Rambaldi; Carmen Ruiz de Elvira; John A Snowden; Jakob Passweg; Jane Apperley; Dietger Niederwieser; Theo Stijnen; Ronald Brand
Journal:  EBioMedicine       Date:  2015-11-19       Impact factor: 8.143

10.  Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT.

Authors:  Andrzej Frankiewicz; Christophe Peczynski; Sebastian Giebel; Alenca Harrington; Gerard Socié; Dietger Niederwieser; Christoph Scheid; Martin Bornhäuser; Nicolaus Kröger; Ahmet Elmaagacli; Boris Afanasyev; Peter Dreger; Claudia Rössig; Didier Blaise; Christian Kratz; Ibrahim Yakoub-Agha; Bernhard Kremens; Charlotte Marie Niemeyer; Gerald Wulf; Igor Blau; Olaf Penack; Hildegard Greinix; Grzegorz W Basak
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.